EUR 185,67
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : As New. Unread book in perfect condition.
EUR 170,03
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New.
Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni
EUR 176,40
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New. In.
EUR 191,60
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New.
EUR 191,40
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : As New. Unread book in perfect condition.
EUR 208,40
Quantité disponible : 4 disponible(s)
Ajouter au panierEtat : New. pp. 280.
EUR 141,20
Quantité disponible : 5 disponible(s)
Ajouter au panierTaschenbuch. Etat : Neu. Immunogenicity of Biopharmaceuticals | Marco Weert (u. a.) | Taschenbuch | Biotechnology: Pharmaceutical Aspects | xii | Englisch | 2010 | Springer | EAN 9781441926081 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.
Langue: anglais
Edité par Springer New York, Springer US, 2010
ISBN 10 : 1441926089 ISBN 13 : 9781441926081
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
EUR 168,73
Quantité disponible : 1 disponible(s)
Ajouter au panierTaschenbuch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - A particular issue for biopharmaceuticals that has not been addressed comprehensively in any book, is the potential of an immune response to the biopharmaceutical product. That is, the human body marks the drug as a foreign body, and develops antibodies against the drug. These antibodies may be relatively harmless, but may also cross-react with the endogenous compound, causing autoimmunogenicity. Recent adverse experiences in Europe with Janssen-Ortho's blockbuster product Eprex has increased the attention towards potential immunogenicity of biopharmaceuticals, above all from the regulatory agencies.This book is intended to give a broad overview of the current state-of-the-art regarding the immune response to biopharmaceuticals. The chapters range from an overview of the immune system and factors that may trigger the immune system, via detection of antibodies and clinical implications, to various case examples and the regulatory view on immunogenicity.
Vendeur : Brook Bookstore On Demand, Napoli, NA, Italie
EUR 126,26
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : new. Questo è un articolo print on demand.
Langue: anglais
Edité par Springer New York, Springer US Nov 2010, 2010
ISBN 10 : 1441926089 ISBN 13 : 9781441926081
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
EUR 160,49
Quantité disponible : 2 disponible(s)
Ajouter au panierTaschenbuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -A particular issue for biopharmaceuticals that has not been addressed comprehensively in any book, is the potential of an immune response to the biopharmaceutical product. That is, the human body marks the drug as a foreign body, and develops antibodies against the drug. These antibodies may be relatively harmless, but may also cross-react with the endogenous compound, causing autoimmunogenicity. Recent adverse experiences in Europe with Janssen-Ortho's blockbuster product Eprex has increased the attention towards potential immunogenicity of biopharmaceuticals, above all from the regulatory agencies.This book is intended to give a broad overview of the current state-of-the-art regarding the immune response to biopharmaceuticals. The chapters range from an overview of the immune system and factors that may trigger the immune system, via detection of antibodies and clinical implications, to various case examples and the regulatory view on immunogenicity. 280 pp. Englisch.
Vendeur : moluna, Greven, Allemagne
EUR 136,16
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. First book to address the potential of an immune response to the biopharmaceutical productImmunogenicity of Biopharmaceuticals is the first book to comprehensively address the potential of an immune response to biopharmaceuticals. It is intended to g.
Vendeur : Majestic Books, Hounslow, Royaume-Uni
EUR 218,56
Quantité disponible : 4 disponible(s)
Ajouter au panierEtat : New. Print on Demand pp. 280 66:B&W 7 x 10 in or 254 x 178 mm Perfect Bound on White w/Gloss Lam.
Langue: anglais
Edité par Springer New York, Springer US Nov 2010, 2010
ISBN 10 : 1441926089 ISBN 13 : 9781441926081
Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagne
EUR 160,49
Quantité disponible : 1 disponible(s)
Ajouter au panierTaschenbuch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -A particular issue for biopharmaceuticals that has not been addressed comprehensively in any book, is the potential of an immune response to the biopharmaceutical product. That is, the human body marks the drug as a foreign body, and develops antibodies against the drug. These antibodies may be relatively harmless, but may also cross-react with the endogenous compound, causing autoimmunogenicity. Recent adverse experiences in Europe with Janssen-Orthös blockbuster product Eprex has increased the attention towards potential immunogenicity of biopharmaceuticals, above all from the regulatory agencies.This book is intended to give a broad overview of the current state-of-the-art regarding the immune response to biopharmaceuticals. The chapters range from an overview of the immune system and factors that may trigger the immune system, via detection of antibodies and clinical implications, to various case examples and the regulatory view on immunogenicity.Springer-Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 280 pp. Englisch.
Vendeur : Biblios, Frankfurt am main, HESSE, Allemagne
EUR 220,09
Quantité disponible : 4 disponible(s)
Ajouter au panierEtat : New. PRINT ON DEMAND pp. 280.